drugset / Trial / NCT01133522

Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin

NCT01133522

Phase 1 Completed 60 enrolled Amgen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the safety and tolerability of multiple doses of evolocumab when given as an add-on to stable statin therapy.

Timeline

Start
2010-06-01
Primary completion
2011-09-14
Completion
2011-09-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Evolocumab Monoclonal antibody 14 mg Subcutaneous
Subject Evolocumab Monoclonal antibody 35 mg Subcutaneous
Subject Evolocumab Monoclonal antibody 140 mg Subcutaneous
Subject Evolocumab Monoclonal antibody 280 mg Subcutaneous
Subject Evolocumab Monoclonal antibody 420 mg Subcutaneous

Indications